Patents, Not Patients: Why the Cheap Treatment Rarely Gets the Trial

A records-over-spin look at a structural problem in medicine: when a treatment can't be patented, the expensive human trials that would prove — or disprove — it often never get funded. So it stalls at "promising," and you never hear about it. This is not medical advice. Every claim below is tied to the primary research with the honest evidence level stated. Bring questions to your doctor; don't change a prescription off an article.

The pattern

A late-stage clinical trial costs tens to hundreds of millions of dollars. A company pays for that when it can patent the treatment and recoup the cost through sales. If a treatment is generic, natural, or off-patent, no company can recoup it — so the trial never gets funded. The result isn't that the treatment failed. It's that we never found out.

Researchers have a name for the gap between "promising lab result" and "proven in humans": the valley of death. Unpatentable treatments fall into it hardest. This isn't a secret conspiracy — it's an openly described incentive structure. NU's job isn't to claim a cure is hidden. It's to show you the real research that exists and how far it actually goes — so you and your doctor see the whole board.

The research is real — here's exactly how far it goes

The metabolism of cancer. That cancer cells preferentially burn glucose is established science — the Warburg effect, ~28,000+ peer-reviewed papers. Using that therapeutically (e.g., ketogenic diet as an adjunct to standard treatment) is actively studied: ~165 registered human trials. Honest level: genuinely researched, complement — not replacement — results mixed and cancer-type-dependent; some tumors adapt to other fuels. Not "starve it easily." But real, and under-discussed with patients.

Metformin — a cheap, off-patent diabetes drug — carries ~4,300 papers on aging/longevity and ~55 registered aging trials. The landmark "TAME" aging trial famously struggled for funding precisely because metformin is generic and no company profits from a positive result. Textbook patents-not-patients.

Oregano oil / carvacrol — ~8,000 papers, strong antibacterial and anti-biofilm activity in the lab. Honest level: solid in vitro/animal; human-dose clinical evidence is thinner, and concentrated oil carries its own safety cautions.

Ivermectin in cancer — ~600 preclinical papers showing anti-tumor activity in cell and animal models. Honest level: preclinical only — essentially no completed human cancer trials. A real lead never funded up the chain. (For COVID it's the opposite story: it WAS tested heavily — ~80 registered trials — and the rigorous ones mostly showed no benefit. Tested-and-failed is not the same as suppressed. Records over spin means saying that too.)

The other direction: treating the symptom can cause the next disease

Medicine itself named this — the prescribing cascade (~500+ papers; one titled literally "Prescribing Cascade as a Therapeutic Error"). You treat one number with a drug; the drug causes a side effect; you treat that with another drug.

A concrete, heavily documented example: some blood-pressure drugs (thiazide diuretics, older beta-blockers) can worsen insulin resistance and raise the risk of new-onset diabetes — tens of thousands of papers on the link. Bandaid the blood pressure, create the blood-sugar problem, add the diabetes drug. Mainstream literature, not fringe.

Cholesterol: essential — and the story is oversimplified

Cholesterol is not a villain molecule. Your brain is ~20% cholesterol by dry weight; your liver makes most of the cholesterol in your body (most isn't from food) because you need it — it's the building block of every steroid hormone, vitamin D, and bile. So "lower it in everyone" deserves scrutiny — and the research provides it: in the elderly, higher LDL is often associated with lower mortality, the "cholesterol paradox," ~21,000+ papers.

The honest both-ways line: for people who've already had a heart attack or are high cardiovascular risk, statins do reduce repeat events in good randomized trials — that part is proven, and nobody should stop a prescribed statin based on a web article. But the blanket "everyone past a threshold needs one," especially in low-risk and very elderly people, is genuinely debated, and the absolute benefit there is small. Both are true. That's the point.

What NU does with this

NU won't tell you cholesterol is harmless or that a spice cures cancer. It surfaces the primary records — the trials, the paper counts, the evidence levels — that the commercial web buries under a scare headline, and that wellness grifters bury under a miracle pitch. One side spins it to zero; the other spins it to a hidden cure. NU shows the receipts and trusts you to think.

Two takeaways, no spin:

1. "No big trial" usually means "no profit to fund one" — not "it failed." Promising, unpatentable leads stall in the valley of death, and you deserve to know they exist.
2. More drugs is not always more health. The prescribing cascade is real and named. "What's the root cause?" is a legitimate medical question, not a fringe one.

Bring any of this to your doctor as questions, not conclusions. Don't start or stop any treatment based on this page. Records over spin — including the records that complicate the story.